293 results
Page 5 of 15
8-K
EX-99.1
gbs ozjdrfv9q
29 May 20
Cardiff Oncology Data Continues to Demonstrate Efficacy of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer Presented at ASCO
12:00pm
8-K
EX-99.1
oza3bl3yqv3fgy2zf
28 May 20
Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer
11:50am
8-K
EX-99.1
jvox1hwq29 u2b
27 May 20
Cardiff Oncology Announces $2.5 Million Equity Investment by Biotech-Focused Fundamental Investor Acorn Bioventures
11:07am
8-K
EX-10.1
779kqqr7pq4u 3n
27 May 20
Cardiff Oncology Announces $2.5 Million Equity Investment by Biotech-Focused Fundamental Investor Acorn Bioventures
11:07am
8-K
EX-99.1
sctufjnwbwi
19 May 20
Cardiff Oncology Announces Private Placement Investment by Board of Directors and Chief Executive Officer
9:28am
8-K
EX-99.1
bkq2m42df0 vgkdtt
13 May 20
Entry into a Material Definitive Agreement
10:59am
8-K
EX-99.1
wvb5l3caqw5c0dgk 36
7 May 20
Trovagene Announces First Quarter 2020 Results and Highlights
4:02pm
8-K
EX-99.1
nqkiiw
6 May 20
Trovagene Announces Changing of Company Name to Cardiff Oncology and Appointment of Mark Erlander, PhD, as Chief Executive Officer
10:29am
8-K
EX-99.01
7j5zbpo73r
28 Apr 20
Other Events
12:22pm
8-K
EX-99.01
5e60xe u9rj
22 Apr 20
Other Events
10:54am
8-K
EX-10.1
24ul5pv
10 Apr 20
Entry into a Material Definitive Agreement
4:08pm
8-K
EX-99.1
3c4gicpuhpa4vfszaw31
1 Apr 20
Other Events
1:54pm
8-K
EX-10.1
cqsy j0ft955omv7
31 Mar 20
Entry into a Material Definitive Agreement
4:05pm
8-K
EX-99.1
ll5bp99
5 Mar 20
Trovagene Announces Three New Nominees for Election to Board of Directors
10:38am
8-K
EX-99.1
rcafhrdoleef nnzrs2
27 Feb 20
Trovagene Announces Fourth Quarter and Full-Year 2019 Results
4:15pm
8-K
EX-99.1
3ljv40
13 Feb 20
Other Events
10:00am
8-K
EX-99.1
u7i kfau0
5 Feb 20
Trovagene to Present New Clinical Data for Onvansertib in Metastatic Castration-Resistant Prostate Cancer at ASCO Genitourinary Cancers Symposium
10:24am
8-K
EX-99.1
ftr5h6t2409zkyhu chz
29 Jan 20
Trovagene Receives Approximately $1.45 Million From Exercise of Warrants
10:51am